Can ziconotide as a N-type voltage-sensitive calcium channel blocker open a new mode for treatment of autism? a hypothesis

Neurosciences

Volumn 16, Issue 1, 2011, Pages 83-

  Ghanizadeh, Ahmad ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL N TYPE; GLUTAMIC ACID; OMEGA CONOTOXIN MVIIA;

ARTICLE; AUTISM; CALCIUM TRANSPORT; CHRONIC PAIN; DRUG EFFECT; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; DRUG SELECTIVITY; HUMAN; HYPOTHESIS; NEUROTRANSMITTER RELEASE;

ANIMALS; AUTISTIC DISORDER; CALCIUM CHANNEL BLOCKERS; HUMANS; OMEGA-CONOTOXINS;

EID: 79951614797     PISSN: 13196138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Ghanizadeh A, Mohammadi MR, Sadeghiyeh T, Shooshtari AA, Akhondzadeh S. Symptoms of children with autism spectrum disorder, a clinical sample. Iran J Psychiatry 2009; 4: 165-169
2. Ghanizadeh A. A preliminary study on screening prevalence of pervasive developmental disorder in schoolchildren in Iran. J Autism Dev Disord 2008; 38: 759-763.
3. Blatt GJ. GABAergic cerebellar system in autism: a neuropathological and developmental perspective. Int Rev Neurobiol 2005; 71: 167-178.
4. Shinohe A, Hashimoto K, Nakamura K, Tsujii M, Iwata Y, Tsuchiya KJ, et al. Increased serum levels of glutamate in adult patients with autism. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1472-1477.
5. Rossignol DA. Novel and emerging treatments for autism spectrum disorders: a systematic review. Ann Clin Psychiatry 2009; 21: 213-236.
6. Wallace MS, Rauck RL, Deer T. Ziconotide combination intrathecal therapy: rationale and evidence. Clin J Pain 2010; 26: 635-644.
7. Schmidtko A, Lotsch J, Freynhagen R, Geisslinger G. Ziconotide for treatment of severe chronic pain. Lancet 2010; 375: 1569-1577.
8. Smith HS, Deer TR. Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain. Ther Clin Risk Manag 2009; 5: 521-534.